An interventional study of Repetitive Transcranial Magnetic Stimulation and Intermittent Theta Burst Stimulation (iTBS) in Depression, Major Depressive Disorder and Major Depressive Episode, sponsored by University of British Columbia. Recruiting at 2 sites in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-25.
Sponsored by University of British Columbia · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Depression by University of British Columbia — 9 open to participants now, 10 under way, 1 of them phase 3. Depression · University of British Columbia.
Among the 34 studies in Depression by University of British Columbia, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2021, is one of 25 with no phase, and was the 22nd registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →9 of the 34 studies in Depression by University of British Columbia are open now, in 1 country. Recruiting first, the newest first:
University of British Columbia · Sites in Canada
Ages 40–80
University of British Columbia · Sites in Canada
Ages 19–70
University of British Columbia · Sites in Canada
Ages 19–65
University of British Columbia · Sites in Canada
Ages 18+
University of British Columbia · Sites in Canada
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 480 is above the median of 81 across 7,089 interventional studies indexed under Depression.
Median enrollment 76 across the 34 interventional studies. Of the 20 that completed or were terminated, 3 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of British Columbia is the lead sponsor of 1,342 studies on the registry; 262 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
2 of the studies in Depression by University of British Columbia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05423275University of British ColumbiaLight and Ion Maintenance In Treatment for Depression (LIMIT-D): Feasibility Study | 2026-12 |
| NCT04999553University of British ColumbiaLeft vs. Right Non-Inferiority Trial | 2027-06-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 34 studies in Depression by University of British Columbia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to test the hypothesis that low-frequency rTMS (LFR) works as well as the established intermittent thetaburst rTMS (iTBS) treatment for treatment resistant depression (TRD).
In this multi-centre, triple-blinded, non-inferiority trial 420 patients with TRD will be recruited at two academic centres (UBC, CAMH). Patients will be randomised to receive either iTBS or LFR for 30 sessions. The primary outcome will be the improvement on a depression scale. Secondary outcome will be improvement of suicidal ideation. A secondary aim is to test the predictive capacity of a novel, easy to implement heart rate based biomarkers (i.e. heart rate variability).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
iTBS to the L-DLPFC
Device: Repetitive Transcranial Magnetic Stimulation · Device: Intermittent Theta Burst Stimulation (iTBS)
1Hz stimulation to the R-DLPFC
Device: Repetitive Transcranial Magnetic Stimulation · Device: Low Frequency Right (LFR)
rTMS will employ the MagPro X100/R30 stimulator equipped with the cool-B70 as we used a cool-B70 in our past non-inferiority trial. The dose will be a 120% rMT in accordance to our latest trial using iTBS. The target area to stimulate will be the right dorsolateral prefrontal cortex (DLPFC) for LFR and the left DLPFC for iTBS as established in prior clinical trials. The localization of both targets will follow the well-established procedures for either R-DLPFC or L-DLPFC using a heuristic method.
Intermittent Theta Burst Stimulation (iTBS)
Low Frequency Right (LFR)
Depression severity
17 item Hamilton Depression Rating Scale (HDRS-17) Change
Time frame: 30 days
Suicidal ideation
Columbia Suicide Severity Rating Scale Screen Version (C-SSRS) Change
Time frame: 30 days
Anxiety severity
Hamilton Anxiety Rating Scale (HAM-A) Change
Time frame: 30 days
Depression severity
Self-rated 16-item Quick Inventory of Depressive Symptoms (QIDS-16) Change
Time frame: 30 days
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2021 (actual). Primary completion is estimated for Jun 2027, 66 months after the start.
Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 66 months is above that.
Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of British Columbia →